Which antibody formats can you produce?

We produce a wide range of recombinant antibody formats: IgG, IgA, IgE, IgM, scFv, Fab, VHH, bispecific antibodies, and Fc-fusion proteins, across different isotypes.

Do you offer customization options (vectors, expression systems, purification, QC)?

Absolutely. Our services are designed to be 100% customizable, from the expression system and vector choice to purification strategies and integrated QC testing.

What is the difference between high-throughput, transient, and stable cell line production?

These three production modes all rely on recombinant technologies but serve distinct needs at different stages of antibody development: High-throughput production: Based on transient expression (genes are not integrated into the host genome), this approach allows the simultaneous generation of dozens to hundreds—even thousands—of antibodies in small amounts (from µg to a few mg, depending on conditions). Fast and cost-effective, it is ideal for early-stage screening projects where the goal is to rapidly eliminate large numbers of candidates. Characterization is typically limited to keep costs and timelines manageable. Transient production: Like high-throughput production, transient production relies on temporary gene expression, but at larger scales (from 30 mL up to several liters). It is generally used to produce a limited number of candidates (from one to a few dozen) in quantities ranging from milligrams to grams. This makes it a perfect choice for intermediate stages such as antibody optimization or lead candidate selection, where detailed characterization is required to support critical decision-making. Stable cell line development: In this method, the gene is permanently integrated into the host cell genome, enabling long-term, high-yield production. Stable cell lines are typically used for large-scale production, from preclinical studies to clinical trials and industrial biomanufacturing. Although it is a longer, more complex, and generally more expensive process, it includes comprehensive characterization due to its strategic role in the drug development value chain.

How do I know which platform is best for my project?

It depends on factors such as the number of antibodies, the required quantity, and your budget. Our experts are here to guide you to the most efficient strategy for your specific goals.

Can I start with transient production and later move to stable cell lines?

Yes. Many projects begin with transient expression and transition to stable cell line development once advanced.

What quality controls and characterizations do you provide?

We offer a wide range of analytical and functional characterizations, providing a full identity card of your antibody. This can include the assessment of several properties such as: Binding activity Identity Purity Stability Monodispersity Glycosylation Endotoxin/sterility Immunogenicity Structure Degradation products

Is your service certified?

Yes. ProteoGenix is ISO 9001:2015 and ISO 14001:2015 certified. This ensures you are working with a partner committed to quality, client satisfaction, and sustainability.

Can I produce antibodies on a royalty-free basis?

Absolutely. All our production services are 100% royalty-free. You pay only for the service, and you remain the full owner of your deliverables. No hidden fees, no royalties, no surprises.

Scientist running recombinant antibody expression in XtenCHO cell culture.

RECOMBINANT ANTIBODY EXPRESSION & PRODUCTION

Recombinant Antibody Production Services

From Screening to Scale-Up

From antibody screening to scale-up, accelerate your projects with tailored recombinant antibody production, purification and quality control.

From €100 per antibody* HTP · Transient · Stable Royalty-free production

Compare Production Options ↓ Get a 2-Minute Estimate

Choose the Right Recombinant Antibody Production Service

Three production approaches for different project needs. Choose your starting point below.

MANY CANDIDATES

High-throughput antibody production

Up to 7,000 antibodiesin parallel

1 mg guaranteed per candidate From 15 days

Explore this service →
SELECTED CANDIDATES

Transient antibody production services

Milligrams to several gramspurified antibody production

From 15 days XtenCHO™ Race platform

Explore this service →
LONG-TERM SUPPLY

Stable cell line development service

1 g/L Guaranteed YieldMultigram-yield expression

Royalty-free From gene to stable cell line: 3–4 months

Explore this service →

WHY PROTEOGENIX

More Than Antibody Expression:
One Partner From Discovery to Production

A connected approach to recombinant antibody production, designed to simplify decisions across project stages.

01

From €100 per antibody*

Transparent, all-inclusive pricing. Understand what is included in your production quote before committing.
02

CHO platform continuity

Move from screening to stable cell line development within a consistent CHO expression approach where suitable.
03

Yield-focused production

Optimize expression to improve the quantity recovered per project; compare cost per mg using project-specific data.
04

100% Royalty-Free Production

No royalties on antibody production, helping you maintain control over your production costs.
05

One partner, end to end

Coordinate gene synthesis, expression, purification and quality control in one project.
06

Dedicated PhD-level expertise

Get scientific guidance on the appropriate expression strategy for your antibody.

SIDE-BY-SIDE COMPARISON

HTP vs Transient Expression vs Stable Cell Line Development

Compare the three recombinant antibody production methods by project stage, scale, throughput and timeline.

Production option	Production capabilities	Applications	Development & terms
Production optionHigh-Throughput Antibody ProductionEarly discovery & candidate screening	Production capabilities Transient — no genome integration µg – mg Multi-well plate Up to 7,000 antibodies in parallel From 15 days	Applications Rapid variant screening Lead candidate selection AI model training datasets Antibody optimization panels	Development & terms Development stage: Early discovery Next stage: Scale up to Transient Expression 100% royalty-free
Production optionTransient ExpressionLead production & characterization	Production capabilities Transient — no genome integration mg – grams 30 mL to multi-liter bioreactors 1 to dozens antibodies From 15 days	Applications Lead production & characterization Antibody engineering validation Preclinical in vitro studies	Development & terms Development stage: Lead optimization Next stage: Scale up to transient expression in bioreactors or Stable Cell line development 100% royalty-free
Production optionStable Cell Line DevelopmentLong-term antibody production	Production capabilities Permanent — stably integrated grams Fed-batches Single clone per cell line 3-4 months	Applications Preclinical studies Regulatory submissions (IND/IVD) Long-term consistent supply	Development & terms Development stage: Preclinical Next stage: Transfer to partner CDMO for GMP manufacturing 100% royalty-free

Not sure which production approach fits your project?

Share your project goals or existing brief. We can help you identify the right next step.

Discuss Your Project →

PRODUCTION FLEXIBILITY

Expression Systems & Antibody Formats

PRIMARY PLATFORM

XtenCHO™ Race (CHO)

Our CHO-based production approach for antibody expression, with continuity across suitable project stages.
OTHER OPTIONS

HEK293 & alternative systems

Discuss host selection based on your molecule, study objectives and technical requirements. Availability is project-dependent.

Antibody formats

IgG1 / IgG2 / IgG4 Bispecific antibodies Multispecific antibodies Fc-fusion proteins Fab scFv VHH

Get a quote now!
Use our price calculator

Complete our 2-minute project calculator to receive a personalized estimate for your recombinant antibody project.

Custom process

A recombinant antibody production workflow customized at every step

A simple, transparent workflow from project definition to purified antibody delivery.

01

Project definition

Define your production requirements

Format, quantity, timeline, application and quality requirements reviewed with your dedicated PhD expert.
02

Production platform

Choose your production method

High-throughput expression, transient production or stable cell line development, according to your project stage and required scale.
03

Gene synthesis & vector

Customize your sequence and expression construct

Codon optimization, gene synthesis and cloning into the selected expression vector.
04

Production & purification

Choose your purification level

Default: Affinity chromatography using Protein A/G.
05

Quality control

Choose your QC level

Default: Quantification by UV280, reducing and non-reducing SDS-PAGE, and purity evaluation.

Proof of monoclonality by VIPS™ for stable cell lines.
06

Delivery

Receive your purified antibodies and complete project documentation

Detailed report and purified antibody samples in PBS, pH 7.5, azide-free and sterilized by membrane filtration.

Stable cell line included with the stable cell line development service.

high-productivity mammalian recombinant expression Xtencho

XtenCHO® Race

Up to 9.7-fold improvement in yield than the market leader CHO System

Our proprietary XtenCHO® Race platform is engineered for high-productivity mammalian transient expression. Internal comparative benchmarks show 1.5- to 9.7-fold improvements in yield, depending on the antibody.

XtenCHO® Race has achieved up to 1.8 g/L for IgG-like antibody production.

1.5- to 9.7-fold
improvement in antibody yield in comparative benchmarks
1.8 g/L
record productivity achieved for an IgG-like antibody

Comparison of the production yield of 10 therapeutic antibodies with XtenCHO® Race vs Market Leader

XtenCHO® Race Case Reports

See our expertise through real antibody production projects

Explore how XtenCHO® Race performs across high-throughput candidate screening and mid-scale production for preclinical development.

High-throughput antibody production case study showing 7.24 mg per 30 mL yield, 18 antibodies expressed and 14-day production using XtenCHO® Race.

High-throughput expression service

Fast-tracking variant selection with XtenCHO® Race small-scale production

7.24 mg / 30 mL
14 days
18 antibodies expressed

A mid-size Canadian biotech developing a therapeutic antibody for colorectal cancer needed to compare the production yields of 18 in-house antibody sequences. XtenCHO® Race small-scale expression enabled rapid yield comparison without using internal production resources.

Result: faster candidate selection with comparable production data across all 18 antibody variants.

Read the case report Explore High-Throughput Production

Mid-scale transient antibody production results with XtenCHO® Race showing 10.63 mg per 200 mL yield, low endotoxin and greater than 90 percent purity.

Transient expression service

Delivering preclinical-grade antibodies with XtenCHO® Race mid-scale production

10.63 mg / 200 mL
<10 EU/mL endotoxin
>90% purity

A pharmaceutical company developing a recombinant antibody for rheumatoid arthritis needed to assess yield robustness during a 200 mL scale-up before advancing the lead candidate toward preclinical validation.

Result: preclinical-grade material meeting defined yield, endotoxin and purity requirements for the next development stage.

Read the case report Explore Transient Production

Want to see whether XtenCHO® Race fits your antibody project?

Discuss your sequence, scale and quality requirements with a PhD expert.

Discuss Your Project

Trusted by 9,000+ Researchers Worldwide

Ramon Llull University, Spain

Nathanaël Rakotoarinoro, PhD, Postdoctoral researcher

“I have collaborated on several occasions with ProteoGenix for the production of recombinant antibodies. I greatly appreciated the responsiveness of the Account Manager, as well as their ability to identify the most appropriate solutions based on our needs and requirements. Overall, ProteoGenix’s services have often exceeded those of market leaders, and I have always been highly satisfied with the quality and quantity of the delivered products. This applies both to the antibodies produced and to the corresponding plasmids re-cloned into our in-house vectors, with a 100% success rate so far.”
LETI Pharma, Spain

Jose Luis Donoso Muñoz, Project Manager

“It was a real pleasure working with the Proteogenix team. Everything went very smoothly, the coordination was close and efficient, and they were always quick to respond to any doubts or questions. We truly appreciated how attentive they were throughout the entire process; at all times, we felt the communication was fluid and proactive. The delivery timelines were perfectly met, which made the collaboration even more seamless. I’d be happy to work together with them again in the future.”
University Hospital Basel, Switzerland

Nicolas Kramer, PhD, Postdoctoral researcher

“Working with ProteoGenix antibody production team has been an outstanding experience. The entire process was smooth, professional, and scientifically rigorous from start to finish. Communication was clear, timelines were met, and the final antibodies were delivered with a great amount of validation data. I truly appreciated ProteoGenix technical expertise and reliability, and I would gladly collaborate again in the future.”

Frequently asked questions

These three production modes all rely on recombinant technologies but serve distinct needs at different stages of antibody development:
- High-throughput production:
Based on transient expression (genes are not integrated into the host genome), this approach allows the simultaneous generation of dozens to hundreds—even thousands—of antibodies in small amounts (from µg to a few mg, depending on conditions). Fast and cost-effective, it is ideal for early-stage screening projects where the goal is to rapidly eliminate large numbers of candidates. Characterization is typically limited to keep costs and timelines manageable.
- Transient production:
Like high-throughput production, transient production relies on temporary gene expression, but at larger scales (from 30 mL up to several liters). It is generally used to produce a limited number of candidates (from one to a few dozen) in quantities ranging from milligrams to grams. This makes it a perfect choice for intermediate stages such as antibody optimization or lead candidate selection, where detailed characterization is required to support critical decision-making.
- Stable cell line development:
In this method, the gene is permanently integrated into the host cell genome, enabling long-term, high-yield production. Stable cell lines are typically used for large-scale production, from preclinical studies to clinical trials and industrial biomanufacturing. Although it is a longer, more complex, and generally more expensive process, it includes comprehensive characterization due to its strategic role in the drug development value chain.
We offer a wide range of analytical and functional characterizations, providing a full identity card of your antibody. This can include the assessment of several properties such as:
- Binding activity
- Identity
- Purity
- Stability
- Monodispersity
- Glycosylation
- Endotoxin/sterility
- Immunogenicity
- Structure
- Degradation products

From €100 per antibody*

*Price available only for the production of 7000 antibodies in parallel

LET’S DISCUSS YOUR PROJECT

Ready to Produce Your Recombinant Antibodies?

Tell us about your antibody project. Our team will help you identify the right approach, from high-throughput screening to transient expression or stable cell line development.

Three production strategies tailored to your needs
From candidate screening to long-term production
Guidance on quantity, timelines and QC requirements

? Not sure where to start?

Already have an antibody sequence, a selected candidate or a project brief? Tell us what you have and what you need to achieve. Our team can help identify the most suitable production approach.